Analysis of the COMPARE-AMI trial: First report of long-term safety of CD133+ cells

Int J Cardiol. 2020 Nov 15;319:32-35. doi: 10.1016/j.ijcard.2020.06.004. Epub 2020 Jun 15.


Background: Data related to long-term safety of intracoronary (IC) injection of CD133+ bone marrow stem cells (BMSC) following an acute myocardial infarction (MI) are still lacking.

Methods: COMPARE-AMI is a double-blind, placebo-controlled phase II clinical trial evaluating the safety and efficacy of IC injection of CD133+ enriched hematopoietic BMSC in patients with ST-elevation myocardial infarction (STEMI) and persistent left ventricular (LV) dysfunction following successful primary percutaneous coronary intervention (PCI). Herein, we report outcomes up to ten years of follow-up.

Results: Between November 2007 and July 2012, we enrolled 38 patients in our study. Males were 89% and the median age was 50.5 years. Baseline left ventricular ejection fraction (LVEF) was 40.0%, and 90% of lesions were located in the left anterior descending (LAD) artery. The median follow-up time was 8.5 years IQR [7.9, 10.0]. Using Kaplan-Meier methods, MACE-free survival up to 10 years was 77.3% overall. IC injection of CD133+ BMSC was associated with a similar event-free survival rate compared to placebo (87.8% vs. 66.3%, p = .37). Two cancer cases in each group were recorded. No malignant arrhythmias were observed.

Conclusions: IC injection of CD133+ BMSC is safe up to 10 years of follow-up. The long-term efficacy needs to be confirmed by a larger randomized trial.

Keywords: Bone marrow-derived CD133+ stem cells; COMPARE-AMI; Cardiac regeneration; Cardiovascular disease; Cell therapy; Myocardial infarction.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • AC133 Antigen
  • Female
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention* / adverse effects
  • Stroke Volume
  • Treatment Outcome
  • Ventricular Dysfunction, Left*
  • Ventricular Function, Left


  • AC133 Antigen
  • PROM1 protein, human